TheraRadar
← Back
Data updated: Jun 28, 2026

AETERNA ZENTARIS

Pharma
Oncology Execution: Good

AETERNA ZENTARIS is a pharmaceutical company focused on Oncology. Key products include MACRILEN.

2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2017)
1 Novel 1 First-in-Class 1 Orphan
See 1 novel approval →
2017 MACRILEN (MACIMORELIN ACETATE) First-in-Class · Orphan

AETERNA ZENTARIS at a Glance

  • Fast trial execution (24 months median completion)

AETERNA ZENTARIS's Key Drugs

AETERNA ZENTARIS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AETERNA ZENTARIS's Recent FDA Approvals

New NDA/BLA approvals for AETERNA ZENTARIS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AETERNA ZENTARIS's Therapeutic Areas

AETERNA ZENTARIS's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 3

AETERNA ZENTARIS's Top Competitors

AETERNA ZENTARIS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology
Novartis big-pharma
Oncology
Merck big-pharma
Oncology
Baxter specialty
Oncology
AbbVie big-pharma
Oncology

AETERNA ZENTARIS Pipeline Snapshot

AETERNA ZENTARIS has 7 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 1 Phase 2 and 3 Phase 1.

3
Phase 3
1
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/7 completed
  • • Speed: 24 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges